Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • MGH - Bethesda Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links

  • About Us
  • Mission & Values
  • Leadership
  • News
  • Careers
  • Partnerships
  • Support
  • Achievements

Latest News

July 20, 2015

Alefacept Preserves Beta Cell Function in Some New-Onset Type 1 Diabetes Patients Out to Two Years

Individuals with new-onset type 1 diabetes who took two courses of alefacept (Amevive®, Astellas Pharma Inc.) soon after diagnosis show preserved beta cell function after two years compared to those who received a placebo. The positive results of the Immune Tolerance Network’s (ITN) T1DAL study [Inducing Remission in New Onset T1DM with Alefacept (Amevive®)], led by Mark Rigby, MD, PhD, of Indiana University were published today in the Journal of Clinical Investigation.

> read more
February 23, 2015

Early Consumption of Peanuts Prevents Peanut Allergy in High-Risk Infants

The results of the Immune Tolerance Network’s (ITN) “Learning Early About Peanut” (LEAP) study published today in the New England Journal of Medicine demonstrate that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy.

> read more
February 04, 2015

ITN Opens Pilot Study to Compare Allergen Challenge Methods (CAT EEC Study)

On Monday the ITN opened a new pilot study to compare two different methods for assessing allergic responses: environmental exposure chambers and nasal allergen challenges. The CAT EEC study, “Cat Pilot Study – Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC),” is being conducted at Inflamax Research, Inc. in Ontario, Canada and led by Drs.

> read more
January 30, 2015

ITN Opens the EXTEND Study in Type 1 Diabetes

A new ITN type 1 diabetes trial opened today at the first site, Sanford Health in Sioux Falls, SD.

> read more
January 27, 2015

Request for Proposals: ITN Seeks Antigen-Specific T Cell Tolerance Assays for Myelin-Associated Antigens in Multiple Sclerosis

The ITN has an interest in antigen-specific T cell tolerance in multiple sclerosis, an autoimmune disease in which autoreactive T cells specific for myelin-associated antigens are thought to play a role in pathogenesis. Assessment of antigen-specific tolerance in multiple sclerosis will require reliable assays to detect and phenotype T cell responses to myelin-associated antigens in a clinical trial setting. To this end, the ITN is seeking assays for assessing functional tolerance and biomarkers of tolerance in antigen-specific CD4 and CD8 effector and regulatory T cells.

> read more
January 21, 2015

Immunotherapy Research in Seattle and the ITN

An article in Seattle Magazine about the landscape for immunotherapy in Seattle gives a nice mention of the Benaroya Research Institute and the Immune Tolerance Network:

> read more
January 05, 2015

Stem Cell Transplants May Halt Progression of Multiple Sclerosis

Washington, DC - Three-year outcomes from an ongoing clinical trial suggest that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, a progressive autoimmune disease in which the immune system attacks the brain and spinal cord.

> read more
November 03, 2014

CALIBRATE Trial for Lupus Nephritis Opens

Last Friday the Immune Tolerance Network (ITN) opened a new combination therapy study in lupus nephritis, CALIBRATE, at University of California, San Francisco (UCSF). The CALIBRATE Study will be led by Drs. Betty Diamond (North Shore Feinstein Institute), David Wofsy (UCSF), Cynthia Aranow (North Shore Feinstein Institute), and Maria Dall’Era (UCSF), and will test a novel regimen of rituximab (Rituxan, Genentech, Inc.) followed by belimumab (BENLYSTA®, GlaxoSmithKline) in patients with refractory lupus nephritis.

> read more
October 29, 2014

Abatacept for Lupus Nephritis (the ACCESS Study)

The results of the ACCESS study, “Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis” sponsored by the Immune Tolerance Network (ITN) and led by Drs.

> read more
October 22, 2014

ITN Will Receive National Academies' Award For TrialShare On October 23rd

The Immune Tolerance Network (ITN) will receive the National Academies' Board on Research Data and Information Challenge Award for 

> read more

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next page Next ›
  • Last page Last »

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2019 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility